Marina Okada
Keio University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Marina Okada.
Stem Cells Translational Medicine | 2014
Natsuko Hemmi; Shugo Tohyama; Kazuaki Nakajima; Hideaki Kanazawa; Tomoyuki Suzuki; Fumiyuki Hattori; Tomohisa Seki; Yoshikazu Kishino; Akinori Hirano; Marina Okada; Ryota Tabei; Rei Ohno; Chihana Fujita; Tomoko Haruna; Shinsuke Yuasa; Motoaki Sano; Jun Fujita; Keiichi Fukuda
Cardiac regenerative therapy with human pluripotent stem cells (hPSCs), such as human embryonic stem cells and induced pluripotent stem cells, has been hampered by the lack of efficient strategies for expanding functional cardiomyocytes (CMs) to clinically relevant numbers. The development of the massive suspension culture system (MSCS) has shed light on this critical issue, although it remains unclear how hPSCs could differentiate into functional CMs using a MSCS. The proliferative rate of differentiating hPSCs in the MSCS was equivalent to that in suspension cultures using nonadherent culture dishes, although the MSCS provided more homogeneous embryoid bodies (EBs), eventually reducing apoptosis. However, pluripotent markers such as Oct3/4 and Tra‐1‐60 were still expressed in EBs 2 weeks after differentiation, even in the MSCS. The remaining undifferentiated stem cells in such cultures could retain a strong potential for teratoma formation, which is the worst scenario for clinical applications of hPSC‐derived CMs. The metabolic purification of CMs in glucose‐depleted and lactate‐enriched medium successfully eliminated the residual undifferentiated stem cells, resulting in a refined hPSC‐derived CM population. In colony formation assays, no Tra‐1‐60‐positive colonies appeared after purification. The nonpurified CMs in the MSCS produced teratomas at a rate of 60%. However, purified CMs never induced teratomas, and enriched CMs showed proper electrophysiological properties and calcium transients. Overall, the combination of a MSCS and metabolic selection is a highly effective and practical approach to purify and enrich massive numbers of functional CMs and provides an essential technique for cardiac regenerative therapy with hPSC‐derived CMs.
Cell Metabolism | 2016
Shugo Tohyama; Jun Fujita; Takako Hishiki; Tomomi Matsuura; Fumiyuki Hattori; Rei Ohno; Hideaki Kanazawa; Tomohisa Seki; Kazuaki Nakajima; Yoshikazu Kishino; Marina Okada; Akinori Hirano; Takuya Kuroda; Satoshi Yasuda; Yoji Sato; Shinsuke Yuasa; Motoaki Sano; Makoto Suematsu; Keiichi Fukuda
Human pluripotent stem cells (hPSCs) are uniquely dependent on aerobic glycolysis to generate ATP. However, the importance of oxidative phosphorylation (OXPHOS) has not been elucidated. Detailed amino acid profiling has revealed that glutamine is indispensable for the survival of hPSCs. Under glucose- and glutamine-depleted conditions, hPSCs quickly died due to the loss of ATP. Metabolome analyses showed that hPSCs oxidized pyruvate poorly and that glutamine was the main energy source for OXPHOS. hPSCs were unable to utilize pyruvate-derived citrate due to negligible expression of aconitase 2 (ACO2) and isocitrate dehydrogenase 2/3 (IDH2/3) and high expression of ATP-citrate lyase. Cardiomyocytes with mature mitochondria were not able to survive without glucose and glutamine, although they were able to use lactate to synthesize pyruvate and glutamate. This distinguishing feature of hPSC metabolism allows preparation of clinical-grade cell sources free of undifferentiated hPSCs, which prevents tumor formation during stem cell therapy.
PLOS ONE | 2014
Tomohisa Seki; Shinsuke Yuasa; Dai Kusumoto; Akira Kunitomi; Yuki Saito; Shugo Tohyama; Kojiro Yae; Yoshikazu Kishino; Marina Okada; Hisayuki Hashimoto; Makoto Takei; Toru Egashira; Masaki Kodaira; Yusuke Kuroda; Atsushi Tanaka; Shinichiro Okata; Tomoyuki Suzuki; Mitsushige Murata; Jun Fujita; Keiichi Fukuda
Induced pluripotent stem cells (iPSCs) have been proposed as novel cell sources for genetic disease models and revolutionary clinical therapies. Accordingly, human iPSC-derived cardiomyocytes are potential cell sources for cardiomyocyte transplantation therapy. We previously developed a novel generation method for human peripheral T cell-derived iPSCs (TiPSCs) that uses a minimally invasive approach to obtain patient cells. However, it remained unknown whether TiPSCs with genomic rearrangements in the T cell receptor (TCR) gene could differentiate into functional cardiomyocyte in vitro. To address this issue, we investigated the morphology, gene expression pattern, and electrophysiological properties of TiPSC-derived cardiomyocytes differentiated by floating culture. RT-PCR analysis and immunohistochemistry showed that the TiPSC-derived cardiomyocytes properly express cardiomyocyte markers and ion channels, and show the typical cardiomyocyte morphology. Multiple electrode arrays with application of ion channel inhibitors also revealed normal electrophysiological responses in the TiPSC-derived cardiomyocytes in terms of beating rate and the field potential waveform. In this report, we showed that TiPSCs successfully differentiated into cardiomyocytes with morphology, gene expression patterns, and electrophysiological features typical of native cardiomyocytes. TiPSCs-derived cardiomyocytes obtained from patients by a minimally invasive technique could therefore become disease models for understanding the mechanisms of cardiac disease and cell sources for revolutionary cardiomyocyte therapies.
PLOS ONE | 2015
Kazuaki Nakajima; Jun Fujita; Makoto Matsui; Shugo Tohyama; Noriko Tamura; Hideaki Kanazawa; Tomohisa Seki; Yoshikazu Kishino; Akinori Hirano; Marina Okada; Ryota Tabei; Motoaki Sano; Shinya Goto; Yasuhiko Tabata; Keiichi Fukuda
Cell transplantation therapy will mean a breakthrough in resolving the donor shortage in cardiac transplantation. Cardiomyocyte (CM) transplantation, however, has been relatively inefficient in restoring cardiac function after myocardial infarction (MI) due to low engraftment of transplanted CM. In order to ameliorate engraftment of CM, the novel transplantation strategy must be invented. Gelatin hydrogel (GH) is a biodegradable water-soluble polymer gel. Gelatin is made of collagen. Although we observed that collagen strongly induced the aggregation of platelets to potentially cause coronary microembolization, GH did not enhance thrombogenicity. Therefore, GH is a suitable biomaterial in the cell therapy after heart failure. To assess the effect of GH on the improvement of cardiac function, fetal rat CM (5×106 or 1x106 cells) were transplanted with GH (10 mg/ml) to infarcted hearts. We compared this group with sham operated rats, CM in phosphate buffered saline (PBS), only PBS, and only GH-transplanted groups. Three weeks after transplantation, cardiac function was evaluated by echocardiography. The echocardiography confirmed that transplantation of 5×106 CM with GH significantly improved cardiac systolic function, compared with the CM+PBS group (fractional area change: 75.1±3.4% vs. 60.7±5.9%, p<0.05), only PBS, and only GH groups (60.1±6.5%, 65.0±2.8%, p<0.05). Pathological analyses demonstrated that in the CM+GH group, CM were efficiently engrafted in infarcted myocardium (p<0.01) and angiogenesis was significantly enhanced (p<0.05) in both central and peripheral areas of the scar. Moreover, quantitative RT-PCR revealed that angiogenic cytokines, such as basic fibroblast growth factor, vascular endothelial growth factor, and hepatocyte growth factor, were significantly enriched in the CM+GH group (p<0.05). Here, we report that GH confined the CM effectively in infarcted myocardium after transplantation, and that CM transplanted with GH improved cardiac function with a direct contraction effect and enhanced angiogenesis.
PLOS ONE | 2014
Yoshikazu Kishino; Tomohisa Seki; Jun Fujita; Shinsuke Yuasa; Shugo Tohyama; Akira Kunitomi; Ryota Tabei; Kazuaki Nakajima; Marina Okada; Akinori Hirano; Hideaki Kanazawa; Keiichi Fukuda
Recently, induced pluripotent stem cells (iPSCs) were established as promising cell sources for revolutionary regenerative therapies. The initial culture system used for iPSC generation needed fetal calf serum in the culture medium and mouse embryonic fibroblast as a feeder layer, both of which could possibly transfer unknown exogenous antigens and pathogens into the iPSC population. Therefore, the development of culture systems designed to minimize such potential risks has become increasingly vital for future applications of iPSCs for clinical use. On another front, although donor cell types for generating iPSCs are wide-ranging, T cells have attracted attention as unique cell sources for iPSCs generation because T cell-derived iPSCs (TiPSCs) have a unique monoclonal T cell receptor genomic rearrangement that enables their differentiation into antigen-specific T cells, which can be applied to novel immunotherapies. In the present study, we generated transgene-free human TiPSCs using a combination of activated human T cells and Sendai virus under defined culture conditions. These TiPSCs expressed pluripotent markers by quantitative PCR and immunostaining, had a normal karyotype, and were capable of differentiating into cells from all three germ layers. This method of TiPSCs generation is more suitable for the therapeutic application of iPSC technology because it lowers the risks associated with the presence of undefined, animal-derived feeder cells and serum. Therefore this work will lead to establishment of safer iPSCs and extended clinical application.
Stem cell reports | 2017
Shugo Tohyama; Jun Fujita; Chihana Fujita; Miho Yamaguchi; Sayaka Kanaami; Rei Ohno; Kazuho Sakamoto; Masami Kodama; Junko Kurokawa; Hideaki Kanazawa; Tomohisa Seki; Yoshikazu Kishino; Marina Okada; Kazuaki Nakajima; Sho Tanosaki; Shota Someya; Akinori Hirano; Shinji Kawaguchi; Eiji Kobayashi; Keiichi Fukuda
Summary Cardiac regenerative therapies utilizing human induced pluripotent stem cells (hiPSCs) are hampered by ineffective large-scale culture. hiPSCs were cultured in multilayer culture plates (CPs) with active gas ventilation (AGV), resulting in stable proliferation and pluripotency. Seeding of 1 × 106 hiPSCs per layer yielded 7.2 × 108 hiPSCs in 4-layer CPs and 1.7 × 109 hiPSCs in 10-layer CPs with pluripotency. hiPSCs were sequentially differentiated into cardiomyocytes (CMs) in a two-dimensional (2D) differentiation protocol. The efficiency of cardiac differentiation using 10-layer CPs with AGV was 66%–87%. Approximately 6.2–7.0 × 108 cells (4-layer) and 1.5–2.8 × 109 cells (10-layer) were obtained with AGV. After metabolic purification with glucose- and glutamine-depleted and lactate-supplemented media, a massive amount of purified CMs was prepared. Here, we present a scalable 2D culture system using multilayer CPs with AGV for hiPSC-derived CMs, which will facilitate clinical applications for severe heart failure in the near future.
International Journal of Cardiology | 2014
Toru Egashira; Shinji Makino; Akira Kunitomi; Marina Okada; Yuichiro Maekawa; Keiichi Fukuda
Translational Medicine Communications | 2017
Akinori Hirano; Jun Fujita; Hideaki Kanazawa; Shinji Kawaguchi; Noriko Handa; Yoshitake Yamada; Shigeo Okuda; Shuji Hishikawa; Takumi Teratani; Satoshi Kunita; Shugo Tohyama; Tomohisa Seki; Ryota Tabei; Kazuaki Nakajima; Yoshikazu Kishino; Marina Okada; Kazuma Okamoto; Hideyuki Shimizu; Eiji Kobayashi; Keiichi Fukuda
Circulation | 2017
Ryota Tabei; Hideaki Kanazawa; Jun Fujita; Shugo Tohyama; Akinori Hirano; Shinji Kawaguchi; Kazuaki Nakajima; Tomohisa Seki; Yoshikazu Kishino; Marina Okada; Hideyuki Shimizu; Eiji Kobayashi; Yasuhiko Tabata; Keiichi Fukuda
Journal of Cardiac Failure | 2014
Kazuaki Nakajima; Jun Fujita; Makoto Matsui; Shugo Tohyama; Yoshikazu Kishino; Marina Okada; Akinori Hirano; Tomohisa Seki; Yasuhiko Tabata; Keiichi Fukuda